2024
Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose
Bloom J, Pantouris G, He M, Aljabari B, Mishra L, Manjula R, Parkins A, Lolis E, Al-Abed Y. Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose. Molecular Medicine 2024, 30: 43. PMID: 38539088, PMCID: PMC10976746, DOI: 10.1186/s10020-024-00803-0.Peer-Reviewed Original ResearchConceptsMode of inhibitionAllosteric inhibitorsActive site pocketMigration inhibitory factorSite pocketInhibitory factorProtein crystallographyTautomerase active siteOxidative stressT-614Murine modelDrug modePleiotropic cytokineNon-competitive type of inhibitionAPAP overdoseActive siteMacrophage migration inhibitory factorInhibition constantType of inhibitionInhibitor of macrophage migration inhibitory factorKinetic analysisBackgroundMacrophage migration inhibitory factorAcetaminophen overdoseIn vivo experimentsMultiple small molecule inhibitors
2020
Induction of posterior vitreous detachment (PVD) by non-enzymatic reagents targeting vitreous collagen liquefaction as well as vitreoretinal adhesion
Santra M, Sharma M, Katoch D, Jain S, Saikia U, Dogra M, Luthra-Guptasarma M. Induction of posterior vitreous detachment (PVD) by non-enzymatic reagents targeting vitreous collagen liquefaction as well as vitreoretinal adhesion. Scientific Reports 2020, 10: 8250. PMID: 32427865, PMCID: PMC7237681, DOI: 10.1038/s41598-020-64931-3.Peer-Reviewed Original ResearchConceptsPosterior vitreous detachmentInduction of posterior vitreous detachmentInternal Limiting MembraneCollagen-binding domainVitreous detachmentCortical vitreousVitreoretinal adhesionPharmacologic vitreolysisToxic to retinal cellsEffects of ocriplasminVitreo-retinal adhesionInhibition of tumor cell invasionPosterior cortical vitreousBinding domainTumor cell invasionSynthetic RGD-containing peptideRetinal cellsRGD-containing peptidesRetinal surfaceVitreous liquefactionClinical reagentsEx vivoVitreousIn vivo experimentsTherapeutic use
2008
The efficacy of combination therapy using adeno-associated virus—interferon β and trichostatin A in vitro and in a murine model of neuroblastoma
Hamner J, Sims T, Cutshaw A, Dickson P, Rosati S, McGee M, Ng C, Davidoff A. The efficacy of combination therapy using adeno-associated virus—interferon β and trichostatin A in vitro and in a murine model of neuroblastoma. Journal Of Pediatric Surgery 2008, 43: 177-183. PMID: 18206478, DOI: 10.1016/j.jpedsurg.2007.09.048.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsBlotting, WesternCell Line, TumorCombined Modality TherapyDisease Models, AnimalGenetic TherapyHumansHydroxamic AcidsIn Vitro TechniquesInterferon-betaMaleMiceMice, SCIDNeuroblastomaProbabilityRandom AllocationSensitivity and SpecificityXenograft Model Antitumor AssaysConceptsSevere combined immune deficiencyTrichostatin AHIFN-betaIFN-betaRetroperitoneal neuroblastomaMurine modelIncreased expression of p21(WAF1Interferon-betaEfficacy of combination therapyMurine model of neuroblastomaCombination-treated tumorsStandard chemotherapeutic regimensCells treated with trichostatin ATrichostatin A in vitroCombined immune deficiencyGene therapy approachesIn vivo experimentsModel of neuroblastomaTreated with vehicleCell linesNeuroblastoma cells in vitroWestern blottingHistone deacetylase inhibitorsHuman neuroblastoma cells in vitroExpression of p21(WAF1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply